Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TBPH | Theravance Biopharma, Inc.

Healthcare | Biotechnology | Cayman Islands | NASD

Index	RUT	P/E	-	EPS (ttm)	-1.05	Insider Own	3.60%	Shs Outstand	56.68M	Perf Week	1.22%
Market Cap	519.09M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	-0.86%	Shs Float	45.84M	Perf Month	-4.91%
Income	-68.00M	PEG	-	EPS next Q	-0.21	Inst Own	98.30%	Short Float / Ratio	19.63% / 19.72	Perf Quarter	-15.02%
Sales	51.30M	P/S	10.12	EPS this Y	66.90%	Inst Trans	-0.34%	Short Interest	9.00M	Perf Half Y	-11.85%
Book/sh	4.94	P/B	1.84	EPS next Y	51.90%	ROA	147.50%	Target Price	13.40	Perf Year	-9.71%
Cash/sh	2.94	P/C	3.10	EPS next 5Y	-	ROE	220.80%	52W Range	8.76 - 12.03	Perf YTD	-18.81%
Dividend	-	P/FCF	-	EPS past 5Y	25.40%	ROI	-21.50%	52W High	-24.27%	Beta	0.44
Dividend %	-	Quick Ratio	7.80	Sales past 5Y	27.30%	Gross Margin	-	52W Low	4.05%	ATR	0.29
Employees	111	Current Ratio	7.80	Sales Q/Q	23.40%	Oper. Margin	-	RSI (14)	40.70	Volatility	2.32% 3.20%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	7.60%	Profit Margin	-	Rel Volume	0.81	Prev Close	9.01
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 07 AMC	Payout	0.00%	Avg Volume	456.33K	Price	9.11
Recom	2.00	SMA20	-4.33%	SMA50	-5.78%	SMA200	-13.38%	Volume	367,605	Change	1.11%

Date	Action	Analyst	Rating Change	Price Target Change
May-23-22	Initiated	SVB Leerink	Outperform	$12
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral	$12
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight	$7
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight	$27 → $14
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform	$42 → $14
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$32
Jul-07-20	Initiated	JP Morgan	Overweight	$29
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight	$30
May-13-20	Initiated	Cowen	Outperform	$42
Jan-08-20	Reiterated	H.C. Wainwright	Buy	$25 → $30
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral	$22 → $18
Oct-29-19	Initiated	H.C. Wainwright	Buy	$25
Mar-29-18	Resumed	Piper Jaffray	Overweight	$45
Aug-17-17	Initiated	Evercore ISI	Outperform	$45
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight	$55
May-11-17	Reiterated	Needham	Buy	$40 → $45
Dec-21-16	Initiated	Needham	Buy	$40
Nov-03-16	Initiated	Piper Jaffray	Overweight
Oct-12-16	Downgrade	Robert W. Baird	Neutral → Underperform	$19 → $24
Aug-03-16	Downgrade	BofA/Merrill	Neutral → Underperform

Show Previous Ratings

Sep-06-23 11:30AM	Theravance Bio (TBPH) Down 2.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-31-23 05:55PM	12 High Growth Value Stocks to Buy According to Seth Klarman (Insider Monkey)
Aug-29-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Aug-28-23 06:05AM	Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
Aug-09-23 06:25AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2023 Earnings Call Transcript (Insider Monkey)
09:54AM	Loading…
Aug-08-23 09:54AM	Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss (Zacks)
Aug-07-23 05:25PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:25PM	Theravance Bio: Q2 Earnings Snapshot (AP Finance)
04:05PM	Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Aug-01-23 10:00AM	Top Stocks for August 2023 (Investopedia)
Jul-24-23 06:00AM	Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023 (PR Newswire)
Jul-03-23 09:00AM	Top Growth Stocks for July 2023 (Investopedia)
Jun-08-23 11:14AM	Top Healthcare Stocks for June 2023 (Investopedia)
Jun-07-23 11:30AM	Why Is Theravance Bio (TBPH) Down 3.8% Since Last Earnings Report? (Zacks)
May-18-23 01:50PM	Top Pharmaceutical Stocks for Q2 2023 (Investopedia)
03:41PM	Loading…
May-11-23 03:41PM	Takeda Moves Out From Licensing Agreement With Theravance Biopharma (Benzinga)
10:45AM	Top Small-Cap Stocks for May 2023 (Investopedia)
May-10-23 11:34AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2023 Earnings Call Transcript (Insider Monkey)
06:03AM	Theravance Biopharma First Quarter 2023 Earnings: US$0.35 loss per share (vs US$0.34 loss in 1Q 2022) (Simply Wall St.)
May-09-23 06:00PM	Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy (PR Newswire)
09:24AM	Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates (Zacks)
May-08-23 05:55PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
May-04-23 10:00AM	Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-01-23 10:01AM	Earnings Preview: Theravance Biopharma (TBPH) Q1 Earnings Expected to Decline (Zacks)
Apr-24-23 06:00AM	Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023 (PR Newswire)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia)
Apr-17-23 07:47AM	Theravance Biopharma, Inc.'s (NASDAQ:TBPH) Share Price Not Quite Adding Up (Simply Wall St.)
Apr-14-23 04:23AM	4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-11-23 04:05PM	Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors (PR Newswire)
06:00AM	Loading…
Apr-10-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Mar-31-23 12:41PM	Top Small-Cap Stocks for April 2023 (Investopedia)
11:30AM	ImmunoGen (IMGN) Down 16.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-30-23 05:22PM	Top Healthcare Stocks for April 2023 (Investopedia)
11:30AM	Why Is Corcept (CORT) Up 9.6% Since Last Earnings Report? (Zacks)
Mar-29-23 11:30AM	Theravance Bio (TBPH) Down 2% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-10-23 06:56AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 02:50PM	Top Healthcare Stocks for March 2023 (Investopedia)
Mar-02-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Feb-28-23 02:17PM	Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates (Zacks)
01:33PM	Theravance Biopharma Finally Shelves Failed JAK Inhibitor Program, Lays Off Staff (Benzinga)
Feb-27-23 06:15PM	Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.99%
04:05PM	Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update (PR Newswire)
11:26AM	UPDATE 1-Irenic Capital urges Theravance to conduct review, add shareholder to board (Reuters)
09:00AM	Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review (Business Wire)
Feb-23-23 07:46AM	4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates (Zacks)
Feb-21-23 06:00AM	Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 (PR Newswire)
Feb-16-23 10:01AM	Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-15-23 10:00AM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-09-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jan-09-23 06:00AM	Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets (PR Newswire) -6.96%
Dec-25-22 09:39AM	Shareholders in Theravance Biopharma (NASDAQ:TBPH) are in the red if they invested five years ago (Simply Wall St.)
Dec-07-22 11:30AM	Why Is Theravance Bio (TBPH) Up 1.6% Since Last Earnings Report? (Zacks)
Nov-22-22 04:15PM	Theravance Biopharma, Inc. Announces Final Results of Tender Offer (PR Newswire)
Nov-18-22 06:00AM	Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer (PR Newswire)
Nov-11-22 08:20AM	We Might See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH) Soon (Simply Wall St.)
Nov-08-22 08:34AM	Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss (Zacks)
Nov-07-22 05:45PM	Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer (PR Newswire)
Nov-02-22 04:30PM	Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System (PR Newswire)
Oct-31-22 06:00AM	Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022 (PR Newswire)
Oct-27-22 10:02AM	Pacira (PCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-26-22 10:02AM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-25-22 06:00AM	Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System (PR Newswire)
Sep-28-22 06:00AM	Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares (PR Newswire)
Sep-20-22 09:36AM	Company News for Sep 20, 2022 (Zacks)
Sep-19-22 02:28PM	Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings (Benzinga)
07:22AM	UPDATE: Theravance Biopharma plans $250 million capital return program; stock jumps 3% premarket (MarketWatch)
06:00AM	Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program (PR Newswire)
Sep-08-22 11:30AM	Catalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-06-22 06:00AM	Theravance Biopharma to Present at Upcoming Investor Conferences (PR Newswire)
Aug-14-22 08:06AM	Need To Know: Analysts Are Much More Bullish On Theravance Biopharma, Inc. (NASDAQ:TBPH) Revenues (Simply Wall St.)
Aug-05-22 11:53AM	Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline (Zacks) -7.81%
Aug-04-22 07:25PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Jul-28-22 06:00AM	Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022 (PR Newswire)
Jul-27-22 10:01AM	Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-26-22 10:01AM	Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
08:11AM	Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023 (PR Newswire)
Jul-18-22 10:20AM	The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable (Simply Wall St.)
Jul-14-22 06:04PM	Why 2 drug royalty deals worth close to $2 billion could signal the future (American City Business Journals)
08:58AM	Theravance sets up deal to sell rights to asthma drug to Royalty Pharma (MarketWatch)
Jul-13-22 05:29PM	Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests (Benzinga)
04:25PM	Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million (GlobeNewswire)
04:05PM	Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value (PR Newswire)
08:00AM	Certara Appoints Eran Broshy as New Independent Board Member (GlobeNewswire)
Jul-11-22 05:07PM	How this Peninsula company is turning lung drug royalties into acquisitions (American City Business Journals)
Jun-06-22 08:38AM	Is the Options Market Predicting a Spike in Theravance (TBPH) Stock? (Zacks)
May-13-22 01:57PM	Theravance Biopharma, Inc. (NASDAQ:TBPH) About To Shift From Loss To Profit (Simply Wall St.)
May-06-22 04:15PM	Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates (Zacks)
May-05-22 07:15PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -5.53%
04:05PM	Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
May-04-22 06:30AM	NICE Investigate Helps British Transport Police Streamline Management of Digital Evidence and Investigations to Keep UK Railways Safe from Crime (Business Wire)
May-02-22 06:30AM	NICE CXone Digitizes Contact Center Operations for Regional Australia Bank (Business Wire) +5.60%
06:00AM	Theravance Biopharma to Report First Quarter 2022 Financial Results on May 5, 2022 (PR Newswire)
Apr-26-22 03:01PM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-13-22 06:30AM	NICE and Deutsche Telekom Global Business Announce Comprehensive Partnership to Bring the Power of CXone to Enterprises Across Europe (Business Wire) +5.06%
Apr-12-22 06:30AM	NICE Actimize Positioned as Highest-Scoring Vendor Across Technology Excellence Metrics in 2022 Quadrant Knowledge Anti-Money Laundering Report (Business Wire)
Apr-11-22 06:30AM	NICE Enlighten XO Awarded 2022 CUSTOMER Magazine Product of the Year Award (Business Wire)
Apr-06-22 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire) +5.77%

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Sep 14	Sale	9.89	2,482	24,547	336,803	Sep 18 06:08 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Aug 22	Sale	9.47	1,807	17,112	340,566	Aug 24 06:05 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Aug 11	Sale	9.99	2,322	23,197	349,746	Aug 15 06:09 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Jul 14	Sale	9.84	2,322	22,848	352,068	Jul 18 06:14 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Jun 14	Sale	10.69	2,322	24,822	354,390	Jun 16 06:14 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jun 08	Sale	11.13	1,790	19,923	352,833	Jun 12 06:08 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	May 15	Sale	11.26	2,322	26,146	367,172	May 17 06:17 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Apr 14	Sale	11.88	2,323	27,597	369,494	Apr 18 05:49 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Mar 14	Sale	10.32	2,323	23,973	371,817	Mar 16 07:04 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Mar 09	Sale	10.20	4,000	40,800	360,190	Mar 13 05:57 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Mar 06	Sale	10.05	2,323	23,346	374,140	Mar 08 07:34 PM
Winningham Rick E	CHIEF EXECUTIVE OFFICER	Dec 14	Sale	11.19	50,000	559,500	1,350,797	Dec 16 07:36 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Dec 01	Sale	10.73	2,084	22,361	313,520	Dec 05 05:59 PM
Hindman Andrew A.	SVP, CHIEF FINANCIAL OFFICER	Nov 18	Sale	11.02	65,000	716,242	409,771	Nov 22 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TBPH | Theravance Biopharma, Inc.

Upgrade your FINVIZ experience